ResearchMoz presents this most up-to-date research on Global Depressive Disorder Market: Industry Analysis & Outlook (2016-2020).
Depression is a serious mood disorder, affecting the ability to think, feel, and handle situations like sleeping, eating, or working. It is a mood disorder that causes a persistent feeling of sadness and loss of interest. It builds up a very negative perspective in the way of thinking in every single thing and damages a person’s ability to see brighter versions of any situation in life. It is of various types like major depressive disorder (MDD), perinatal depression, psychotic depression, seasonal depression and bipolar depression.
To be diagnosed with depression, the symptoms must be present for at least two weeks. It may require long-term treatment for years. There is no single cause of depression; it is likely an outcome from combinations of genetic, biochemical, environmental and physiological factors. There are several ways of treating depression depending upon each individual’s characteristics & symptoms. Most people feel better with medication, psychological counseling or both.
The global depressive disorder market is expected to grow and overcome falling revenues due to patent expiry with better innovative drugs and therapies. The US has highest depression disorder prevalence along with highest prevalence of bipolar depression & schizophrenia. With growing awareness and better access to medical facilities, the depressive disorder market is expected to grow worldwide, especially in Asia-Pacific region.
The key factors driving the growth of the depressive disorder market includes increased smoking prevalence, rising healthcare expenditure, growing female population, increasing spending on medicines and rising number of prescription drugs. However, there are certain factors hindering the growth of the market like patent expiry, severe side effects of drugs, and tough regulations. Major trends of the market include novel drug approvals, major drugs in pipeline, and growing public awareness.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=784698
The report offers an in-depth analysis of the “Global Depressive Disorder Market” segmented into global and regional markets. Competition is concentrated in the hands of few major pharmaceutical companies out of which Pfizer Inc., AstraZeneca, Eli Lilly and company, and Lundbeck have been covered in the report.
Table of Content
1. Market Overview
1.1 Introduction
1.2 Types
1.3 Causes & Symptoms
1.4 Diagnosis & Treatment
2. Global Market
2.1 Global Depressive Disorder Market by Value
2.2 Global Depressive Disorder Market Forecast by Value
2.3 Global Depressive Disorder Market by Region
2.4 Global Anti-Depressant Drug Market by Value
2.5 Global Anti-Depressant Drug Market Forecast by Value
2.6 Global Anti-Psychotic Drug Market by Value
2.7 Global Anti-Psychotic Drug Market Forecast by Value
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Depression is a serious mood disorder, affecting the ability to think, feel, and handle situations like sleeping, eating, or working. It is a mood disorder that causes a persistent feeling of sadness and loss of interest. It builds up a very negative perspective in the way of thinking in every single thing and damages a person’s ability to see brighter versions of any situation in life. It is of various types like major depressive disorder (MDD), perinatal depression, psychotic depression, seasonal depression and bipolar depression.
To be diagnosed with depression, the symptoms must be present for at least two weeks. It may require long-term treatment for years. There is no single cause of depression; it is likely an outcome from combinations of genetic, biochemical, environmental and physiological factors. There are several ways of treating depression depending upon each individual’s characteristics & symptoms. Most people feel better with medication, psychological counseling or both.
The global depressive disorder market is expected to grow and overcome falling revenues due to patent expiry with better innovative drugs and therapies. The US has highest depression disorder prevalence along with highest prevalence of bipolar depression & schizophrenia. With growing awareness and better access to medical facilities, the depressive disorder market is expected to grow worldwide, especially in Asia-Pacific region.
The key factors driving the growth of the depressive disorder market includes increased smoking prevalence, rising healthcare expenditure, growing female population, increasing spending on medicines and rising number of prescription drugs. However, there are certain factors hindering the growth of the market like patent expiry, severe side effects of drugs, and tough regulations. Major trends of the market include novel drug approvals, major drugs in pipeline, and growing public awareness.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=784698
The report offers an in-depth analysis of the “Global Depressive Disorder Market” segmented into global and regional markets. Competition is concentrated in the hands of few major pharmaceutical companies out of which Pfizer Inc., AstraZeneca, Eli Lilly and company, and Lundbeck have been covered in the report.
Table of Content
1. Market Overview
1.1 Introduction
1.2 Types
1.3 Causes & Symptoms
1.4 Diagnosis & Treatment
2. Global Market
2.1 Global Depressive Disorder Market by Value
2.2 Global Depressive Disorder Market Forecast by Value
2.3 Global Depressive Disorder Market by Region
2.4 Global Anti-Depressant Drug Market by Value
2.5 Global Anti-Depressant Drug Market Forecast by Value
2.6 Global Anti-Psychotic Drug Market by Value
2.7 Global Anti-Psychotic Drug Market Forecast by Value
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
No comments:
Post a Comment